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The first important insight into how immunosuppres-School of Medicine
sants act came with the observation by HandschumacherJohns Hopkins University
and associates (1984) that CsA binds to a cytoplasmicBaltimore, Maryland 21205
18 kDa protein designated cyclophilin A. Subsequently,
numerous members of the cyclophilin family, which gen-
erally have larger molecular weights, have been identi-
fied (Stamnes and Zuker, 1990). The second member,The term immunophilin is used to designate receptors
designated cyclophilin B, is 22 kDa and is localizedfor immunosuppressant drugs such as cyclosporin A
together with calreticulin to calciosomes, calcium-stor-(CsA), FK506, and rapamycin. In clinical medicine, im-
ing organelles of the endoplasmic reticulum (Price etmunosuppression is used therapeutically for a variety
al., 1991). The 23 kDa cyclophilin C is greatly enrichedof purposes. One of the most important is the treatment
in the kidney, where it is localized to the endoplasmicof patients undergoing organ transplantation to prevent
reticulum (Friedman and Weissman, 1991). Cyclophilinhost-versus-graft rejection (Morris, 1991; Fung and Starzl,
40 is a component of the inactive form of the glucocorti-1994). Immunosuppression also diminishes symptoms
coid receptor and is believed to function as a chaperoneof autoimmune disease such as myocarditis and glomer-
in this context (Freeman et al., 1996).ulonephritis (Thomsonand Starzl, 1992). Historically, im-
A large body of research had established that themunosuppression was achieved with drugs that inhibit
actions of FK506 and CsA on the immune system func-cell division, as lymphocytes tend to divide more rapidly
tion were essentially identical, with both drugs inhibitingthan mature somatic cells. Accordingly, mitotic inhibi-
the early, calcium-dependent phases involved in IL-2tors employed in cancer chemotherapy, such as metho-
formation. Hence, it was hypothesized that they sharetrexate, have been extensively employed as immuno-
a common receptor. Remarkably, FK506 has no affinitysuppressants, but with significant toxicity. In contrast,
for any of the cyclophilins. Binding studies with [3H]FK506modern immunosuppressants, of which the first widely
revealed that it interacts instead with a small solubleemployed agent was CsA, demonstrate a reasonable
protein designated FK506 binding protein (FKBP) (Hard-degree of selectivity for the immune system.
ing et al., 1989; Siekierka et al., 1989b). The FKBPsModern immunosuppressant drugs are also valuable
demonstrate no amino acid sequence homology nor anytools for elucidating intracellular signaling systems.
major conformational resemblance to the cyclophilins.Many of these drugs act at very low nanomolar concen-
Like the cyclophilins, the FKBPs comprisea large family,trations and so display great selectivity. CsA and FK506
whose most abundant and first identified member ishave clarified how calcineurin, the calcium-dependent
FKBP12, a 12 kDa soluble protein (Harding et al., 1989;phosphatase, regulates the entry of transcription factors
Siekierka et al., 1989b; Kay, 1996). FKBP13 displaysinto the nucleus. Rapamycin has elucidated novel sig-
about 40% amino acid sequence identity to FKBP12 butnaling systems that regulate protein translation.
is localized to the lumen of the endoplasmic reticulumCsA, FK506, and rapamycin are large molecules first
(Jin et al., 1991). FKBP25 is a nuclear protein that inter-
isolated from microbial fermentation broths (Figure 1).
acts with casein kinase II, as well as nucleolin, a nucleo-
CsA and FK506 cause immunosuppression by blocking
lar protein that participates in ribosome formation (Galat
the calcium-dependent activation of antigen-reactive T
et al., 1992; Jin and Burakoff, 1993). FKBP52 (also desig-
cells (Borel et al., 1976; Kay et al., 1983). Rapamycin
nated FKBP59 or hsp56), like cyclophilin-40, is part of
inhibits the clonal proliferation of T cells by preventing the glucocorticoid receptor complex, to which it is linked
signaling through the interleukin-2 (IL-2) receptor (Bierer via the 90 kDa heat shock protein (Tai et al., 1992).
et al., 1990a, 1991). Rapamycin is also an antimitotic Additional family members that have not been as well
agent toward a large number of cell types, and because characterized are FKBP12.6 (Lam et al., 1995) and
of this, it has been explored as an anticancer agent FKBP51-FKBP54 (Smith et al., 1993; Baughman et al.,
(Chen et al., 1992). 1995).
The greatest advances in understanding how these Since rapamycin influences different components of
drugs act came with the identification of the immuno- the immune response than FK506 and CsA, most investi-
philins as their receptors. Initial research was restricted gators assumed that it would have a unique receptor.
to investigations in lymphocytes. Appreciation that con- Surprisingly, rapamycin binds to FKBP12 with greater
centrations of the immunophilins in the brain are 10±50 affinity than FK506 (Dumont et al., 1990a, 1990b; Bierer
times greater than levels in the immune system (Steiner et al., 1991).
et al., 1992) has led to a rapidly developing body of The peculiar pattern of drug interactions with the two
evidence indicating important neural roles for the immu- immunophilin families initially stymied efforts to explain
nophilins. immunosuppressive effects. Researchers looked for
some common property. The first insight was that
cyclophilin A has enzymatic activity, catalyzing the
isomerization of peptide proline residues between cis*To whom correspondence should be addressed.
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Figure 1. Structures of Immunophilin Ligands
and trans conformations, an action that should influence is to form a drug±immunophilin complex that inhibits the
calcineurin phosphatase activity and prevents nuclearprotein folding (Fischer et al., 1989; Takahashi et al.,
1989). CsA inhibits this peptidyl prolyl isomerase, or translocation of the NF-ATs (Figure 2).
Rapamycin Inhibits a Novel Signaling Pathwayrotamase, activity at nanomolar concentrations. FKBP12
also possesses rotamase activity, which is inhibited by that Regulates Protein Translation
How can rapamycin bind to FKBP12 yet differ fromFK506 and rapamycin (Harding et al., 1989; Siekierka
et al., 1989a). Thus, rotamase inhibition might appear FK506 in its immunologic effects? The observation that
rapamycin could compete with FK506 for its intracellularfundamental to immunosuppression.
However, numerous compounds that bind to the im- receptor led to the discovery that rapamycin and FK506
shared FKBP12 as a common receptor (Bierer et al.,munophilins and inhibit their rotamase activity lack im-
munosuppressant effects (Bierer et al., 1990b; Dumont 1990a; Dumont et al., 1990a, 1990b). Unlike FK506, the
FKBP12±rapamycin complex does not bind or inhibitet al., 1992). Moreover, these immunosuppressive drugs
typically act at low nanomolar concentrations, whereas calcineurin. Because low nanomolar concentrations of
rapamycin block signaling in cells that contain micro-tissue levels of some immunophilins are almost micro-
molar, so that in intact tissues, only a very small portion molar concentrations of FKBP12, most investigators
assume that rapamycin, like FK506, acts by a gain-of rotamase activitywould be inhibited (Schreiber, 1991).
In principle, these immunosuppressants might act via of-function mechanism, with the FKBP12±rapamycin
complex binding to another target protein.one of the immunophilins whose tissue density is very
low. Alternatively, one might hypothesize a ªgain-of- To seek such a target, we and others looked for pro-
teins that might bind to FKBP12 only in the presencefunctionº mechanism whereby the drug±immunophilin
complex would bind to a second protein that could not of rapamycin. We identified two proteins that interact
selectively with radiolabeled FKBP12 only when rapa-be influenced by the immunophilin or drug alone.
The first drug±immunophilin target was discovered mycin is present and cloned the cDNA for the larger one,
designated rapamycin and FKBP12 target 1 (RAFT1)by Liu et al. (1991) and Friedman and Weissman (1991),
who showed that complexes of cyclophilin A±CsA and (Sabatini et al., 1994). Independently, Schreiber and col-
leagues (Brown et al., 1994) cloned the cDNA for theFKBP12±FK506 bind to calcineurin, a calcium/calmodu-
lin-activated protein phosphatase, and inhibit its activ- same protein and called it FKBP and rapamycin associ-
ated protein (FRAP). RAFT1/FRAP has subsequentlyity. The relative potencies of FK506, CsA, and related
compounds in inhibiting calcineurin correlate closely been identified by other workers (Chiu et al., 1994; Sa-
bers et al., 1995). RAFT1 is the mammalian homolog ofwith their immunosuppressive potencies, suggesting a
role for calcineurin in their immunosuppressive action. two yeast proteins, Tor1 and Tor2 (target of rapamycin)
(Heitman et al., 1991; Kunz et al., 1993), which whenIn T cells, an important calcineurin substrate is the phos-
phorylated form of the transcription factor family, nu- mutated confer resistance to the lethal effects of rapa-
mycin in yeast. Accordingly, RAFT1 is also referred toclear factor of activated T cells (NF-AT). The NF-ATs
stimulate the transcription of a number of genes required as mammalian Tor (mTor). RAFT1 contains a C-terminal
area that is homologous to the kinase domain of phos-for T cell proliferation, notably IL-2 (Tocci et al., 1989).
However, the NF-AT protein cannot enter the nucleus phatidylinositol-3 kinase (PI-3 kinase) (Brown et al.,
1994; Sabatini et al., 1994) and is the founding mamma-unless it is dephosphorylated by calcineurin. Therefore,
the mechanism of immunosuppression by these drugs lian member of a new family of proteins that includes
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Figure 2. Inhibition of T Cell Activation by
CsA and FK506
Upon engaging the antigen±MHC complex in
the appropriate context, the activated T cell
receptor initiates a cascade of intracellular
signaling events that leads to an influx of cal-
cium into the cytosplasm. The elevated intra-
cellular calcium concentration activates the
calcium-sensitive protein phosphatase cal-
cineurin by promoting the binding of the cal-
cium/calmodulin complex to the phospha-
tase. Active calcineurin dephosphorylates
the NF-AT, allowing its translocation into the
nucleus, where it upregulates the transcrip-
tion of several cytokine genes, including IL-2.
The presence of either the FKBP12±FK506
or the cyclophilin cyclophilin±CsA (Cyp±CsA)
complex inhibits the calcineurin-dependent
dephosphorylation of NF-AT.
the DNA-activated protein kinase (DNA-PKcs) (Hartley S6 protein of the 40S subunit. Phosphorylation of the
S6 protein increases the ribosome's affinity for a subsetet al., 1995) and the protein product of the gene that
is disrupted in the disease ataxia telangiectasia (ATM) of mRNAs containing significant 59 secondary structure
or polypyrimidine tracts (Jefferies et al., 1994; Terada(Lavin et al., 1995). While RAFT1 and the yeast TOR
proteins have lipid kinase activity (Cardenas and Heit- et al., 1994). Rapamycin blocks S6 phosphorylation by
p70 S6 kinase (Chung et al., 1992; Kuo et al., 1992).man, 1995; Sabatini et al., 1995), it is unclear whether
this enzymatic activity is intrinsic to RAFT1/Tor or a Moreover, we found that the p70 S6 kinase is directly
phosphorylated by RAFT1, and this phosphorylation cantightly associated lipid kinase.
Rapamycin's interference with protein translation is be inhibited by rapamycin (Burnett et al., 1998a). There-
fore, one mechanism of translational inhibition by rapa-thought to be the mechanism for its antimitotic activity.
The drug blocks several steps in growth factor actions mycin is directly inhibiting RAFT1-dependent ribosomal
phosphorylation.on translational regulators. Recent work in our labora-
tory and others' has demonstrated that RAFT1 functions All mRNAs have a 7-methylguanosine cap structure
at their 59-end that mediates translation initiation. Thisas a protein kinase that phosphorylates several key reg-
ulators of protein translation (Figure 3). cap is bound by eukaryotic initiation factor (eIF-4E). To
initiate translation, eIF-4E must also bind the eIF-4GOne of the shared effects of mitogenic stimuli is a
rapid phosphorylation of the ribosome, primarily on the protein and thereby recruit the eIF-4F complex to the
Figure 3. Inhibition of Growth Factor±Medi-
ated Translation by Rapamycin
The ability of rapamycin to inhibit protein
translation has been well studied in two sub-
strates of RAFT1, p70 S6 kinase and eukary-
otic initiation factor 4E-binding protein 1(eIF
4E-BP1). The complex of rapamycin and
FKBP12 binds RAFT1 and inhibits its ability
to phosphorylate p70 S6 kinase and 4E-BP1.
Because p70 S6 kinase is active in the phos-
phorylated form, inhibition of RAFT1 kinase
activity decreases p70 S6 kinase activity. A
substrate of p70 S6 kinase relevant to protein
translation is the S6 protein in the 40S subunit
of the ribosome. 4E-BP1 binds to eukaryotic
initiation factor 4E (eIF-4E), the mRNA 7-meth-
ylguanylate (M7-GppN) cap-binding protein,
and inhibits formation of the initiation com-
plex. Phosphorylation by RAFT1 and other
kinases disrupts this interaction and allows
protein translation to begin. Thus, rapamycin
inhibits protein translation via decreasing S6
phosphorylation by p70 S6 kinase and inhib-




mRNA (Sonenberg, 1996). This process can be inhibited cells. Parallel studies of calcineurin mRNA and protein
densities reveal very similar localizations throughout theby the unphosphorylated form of the 4E binding protein
(4E-BP1), also known as Phas-1. When 4E-BP1 is phos- brain, implying a physiological link between calcineurin
and FKBP12.phorylated by RAFT1 (Brunn et al., 1997; Burnett et al.,
1998a) and other mitogen-stimulated kinases, it can no Cyclophilin localizations also resemble calcineurin.
Both are highly concentrated in cerebellar granule cellslonger bind to eIF-4E, and the translation initiation com-
plex is assembled (Beretta et al., 1996; von Manteuffel and in the CA1 area of the hippocampus, as well as in
the olfactory bulb (Goldner and Patrick, 1996). How-et al., 1996). Rapamycin inhibits the phosphorylation of
4E-BP1 by RAFT1 and therefore inhibits the initiation of ever, calcineurin localizations overall resemble those of
FKBP12 more than cyclophilin. For instance, calcineurinprotein translation (Brunn et al., 1997; Burnett et al.,
1998a). and FKBP12 are both highly concentrated in the cau-
date, nucleus accumbens, and olfactory tubercle, whichIn cellular homogenates, RAFT1 is partially soluble
and partially particulate, and so its activity might be display only modest levels of cyclophilin (Dawson et al.,
1994).regulated by translocation between the cytoplasm and
the membrane. In a yeast two-hybrid analysis, we dis- As colocalizations often imply physiologic associa-
tion, cain (calcineurin inhibitor), a recently identified cal-covered that RAFT1 interacts with gephyrin (Sabatini et
al., 1996), first identified as a protein that copurifies with cineurin inhibiting protein, appears to be an important
regulator of this enzyme (Lai et al., 1998). Cain wasthe receptor for the neurotransmitter glycine (Betz et
al., 1994). Gephyrin interacts with a domain of RAFT1 discovered as a protein that binds calcineurin alone
or in complexes with FKBP12 in the yeast two-hybridthat displays considerable homology to the gephyrin
binding site of the glycine receptor. The binding of system and other binding studies. Cain is a large cyto-
solic protein, about 240 kDa, without significant homol-RAFT1 to gephyrin is crucial for its phosphorylation of
p70 S6 kinase and 4E-BP1 because mutations in RAFT1 ogy to any known proteins. A 38 amino acid segment
in the C-terminal region of cain accounts for all of itsthat block its binding to gephyrin also block its ability
to regulate p70 S6 kinase and 4E-BP1 (Sabatini et al., calcineurin binding activity. Accordingly, the large re-
maining portion of cain might serve a scaffolding role,1996).
analogous to A kinase anchoring protein (AKAP)-79,
Neuronal Localizations of Immunophilins Establish which binds calcineurin, as well as protein kinase C and
a Physiologic Link to Calcineurin cAMP-dependent protein kinase (Coghlan et al., 1995;
The discovery that immunosuppressants bind with high Klauck et al., 1996). Microscopic localizations of cain
affinity to immunophilins and stimulate interactions with mRNA are virtually superimposable on those of cal-
calcineurin implies the existence of endogenous ligands cineurin, with more impressive colocalization than be-
for the immunophilins that somehow influence cal- tween calcineurin and FKBP12. Cain inhibits calcineurin
cineurin activity. However, no evidence has yet been noncompetitively at submicromolar concentrations more
obtained for an endogenous small molecule ligand for potently than AKAP-79. Conceivably, cain may serve as
immunophilins. Moreover, the fact that immunosup- a docking site for calcineurin, maintaining the phospha-
pressant drugs influence calcineurin activity does not tase in an inactive form. According to this model, the
necessarily mean that immunophilins normally interact release of calcineurin from cain would provide calcium-
with calcineurin. Evidence for a physiological associa- sensitive phosphatase activity to specific intracellular
tion of immunophilins and calcineurin has come from targets.
studies of brain localizations.
Initial studies monitoring [3H]FK506 binding showed FKBP12 Binds and Regulates Ryanodine, Inositol
1,4,5-Trisphosphate (IP3), and TGFb Receptorsthat FKBP12 levels in immune tissues such as the thy-
mus resemble levels in other peripheral tissues such as Interactions of immunophilins with calcineurin in the
presence of immunosuppressive drugs do not establishthe spleen, heart, kidney, liver, and lung. In contrast,
binding levels in the brain are up to 50 times higher than physiologic roles for mammalian immunophilins. Immu-
nophilins are found in bacteria, yeast, and plants, asin any peripheral tissue, depending on the brain region
examined (Steiner et al., 1992; Dawson et al., 1994). The well as in mammals and in cells lacking calcineurin. This
implies the immunophilins associate with other proteins.more than 10-fold variation in [3H]FK506 binding levels
among various brain regions has been corroborated by One such protein is the ryanodine receptor, a major
intracellular calcium channel that mediates calcium-localization of its mRNA by in situ hybridization (Steiner
et al., 1992). FKBP12 is sufficiently enriched in neurons induced calcium release. Highly purified preparations of
the ryanodine receptor (RyR) consistently retain a verythat extraneuronal levels are not detected routinely.
Highest densities of the FKBP12 transcript occur in the small protein ªcontaminant,º which turned out to be
FKBP12 (Jayaraman et al., 1992). The other major intra-corpus striatum, with comparable levels evident in the
substantia nigra zona compacta (Dawson et al., 1994). cellular calcium channel is the inositol 1,4,5-trisphos-
phate receptor (IP3R). Extensively purified IP3R prepara-Lesioning studies indicate that these localizations re-
flect a very high FKBP12 content in the descending tions also contain tightly associated FKBP12 (Cameron
et al., 1995a).striatonigral pathway. High levels of FKBP12 are found
in the hippocampus, with an enrichment in the CA1 layer. What might be the function of the FKBP12 contained
in IP3 and ryanodine receptor preparations? BiophysicalIn the cerebral cortex, FKBP12 is most prominent in
superficial layers, while in the cerebellum it is present in studies of the RyR by Marks and associates (Brillanteset
al., 1994) reveal that FKBP12 is required for physiologicall cellular layers, with the highest density in the Purkinje
Review
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Figure 4. Regulation of Calcium Channels by
FKBP12 and Calcineurin
The calcium-releasing channels RyR and IP3R
are physiologically complexed with FKBP12
and calcineurin. FKBP12 stabilizes calcium
channels by decreasing the probability of
spontaneous opening and by reducing the
frequency of subconductance states, in which
where the channels are partially open. Cal-
cineurin, anchored to the calcium channels
via FKBP12, modulates the calcium flux by
changing the phosphorylation state of IP3R in
a calcium-dependent manner. Stripping the
FKBP12±calcineurin complex from calcium
channels with FK506 leads to leaky RyR and
IP3R, which exhibit increased probability of
channel opening and presence of multiple
subconductance states.
calcium release. When FKBP12 is dissociated from the AKAP-79 (Coghlan et al., 1995; Klauck et al., 1996).
AKAP-79 exists in a complex together with PKA andRyR by the addition of FK506 or rapamycin, multiple
subconductance states and a higher probability of calcineurin. Strikingly, the calcineurin binding domain in
AKAP-79 resembles the domain in FKBP12 that bindsopening are observed. FKBP12 stabilizes the RyR and
prevents calcium leakage in the absence of receptor to calcineurin, supporting a similar scaffolding role for
the two proteins. How does the IP3R bind to FKBP12?activation. Similarly, stripping FKBP12 from the IP3R by
treatment with FK506 results in an increased flux of Yeast two-hybrid studies have identified the leucine±
proline 1400±1401 dipeptide as the site of interactionscalcium in response to lower concentrations of IP3R
(Cameron et al., 1995a). with FKBP12 (Cameron et al., 1997). Analogous leucyl±
prolyl or valyl±prolyl sequences are conserved in allA physiologic role for the interaction of FKBP12 and
RyR has been established using mice with a targeted subtypes of the IP3R, the RyR, and the type 1 TGFb
receptors, which all interact with FKBP12, indicatingdeletion of FKBP12 (Shou et al., 1998). Disturbances of
calcium conductance of RyRs in skeletal muscle mem- that this sequence is likely a universal ligand selective
for FKBP12 binding. FKBP12 may be more importantbranes from FKBP12-deficient mice resemble those of
purified RyRs in the absence of FKBP12. The defect in as a scaffold linking proteins together than as a peptide
prolyl isomerase enzyme mediating protein folding. De-calcium conductance has apparent clinical relevance,
as FKBP12 deficient mice die prior to, or a few weeks spite extensive investigations, only modest evidence
has accumulated for a physiological role of the immu-after, birth, with severe cardiomyopathy resembling the
cardiac abnormalities of patients treated with FK506 nophilins in regulating protein folding.
Molecular biological characterizations indicate that(Atkison et al., 1995).
The FKBP12 complex with the IP3 and ryanodine re- the IP3R mimics the role of FK506 in promoting the asso-
ciation of calcineurin and FKBP12 (Cameron et al., 1997).ceptors also includes calcineurin. Calcineurin copurifies
with both of these calcium channels, even after exten- The chemical structure of FK506 resembles a leucyl±
proline dipeptide (Schreiber, 1991). Taken together,sive purification procedures (Cameron et al., 1995b). The
IP3R (Ferris et al., 1991) is phosphorylated by several these data support the notion that IP3 and ryanodine
receptors are ªendogenous ligandsº for FKBP12. Thiskinases, including protein kinase C (PKC), protein kinase
A (PKA), and calcium-calmodulin±dependent kinase II would contrast with the common conception that such
endogenous ligands should be small molecules, analo-(CaM-K II). The IP3R also autophosphorylates (Ferris et
al., 1992). Calcineurin, which copurifies with the IP3R, gous to the enkephalin pentapeptides mimicking mor-
phine at the opiate receptor (Snyder, 1977). Since themodulates both its phosphorylation state and its ability
to conduct calcium (Cameron et al., 1995b). Calcineurin IP3R is about 200 times larger than FKBP12, perhaps
the optimal conceptualization would be of FKBP12 asinhibition augments IP3R phosphorylation, especially in
response to PKC. Increased phosphorylation by PKC a ligand for the IP3R rather than vice versa.
Another protein that binds to FKBP12 in a patternand CaM-K II renders IP3 more potent in releasing cal-
cium, whereas PKA phosphorylation makes the receptor resembling the IP3 and ryanodine receptors is the type I
receptor for transforming growth factor±b (TGFb). TGFbless sensitive to IP3 (Ferris et al., 1991). Thus, FKBP12
appears to function as a calcineurin-anchoring protein signaling is transduced by binding and juxtaposing the
type I and type II TGFb receptors, allowing the constitu-for the IP3R, with PKC participating in the complex (Fig-
ure 4). Such a complex would facilitate rapid cycles tive kinase activity of type II to phosphorylate and acti-
vate the type I receptor. Downstream effects of TGFbof phosphorylation and dephosphorylation, leading to
corresponding increased and decreased calcium re- signaling lead to diverse biological consequences in
development and tumorogenesis (MassagueÂ , 1996). Inlease.
The FKBP12±IP3R±calcineurin complex is reminiscent the nervous system, TGFb induces long-term synaptic
facilitation (Zhang et al., 1997), protects hippocampalof those associated with the A kinase±anchoring protein
Neuron
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Figure 5. Inhibition of nNOS Activity by FK506
and CsA
Influx of calcium through NMDA receptors ac-
tivates the calcium-sensitive protein phos-
phatase calcineurin by stimulating its binding
to the calcium/calmodulin complex. Acti-
vated calcineurin dephosphorylates nNOS,
increasing its catalytic activity. The subse-
quent increase in NO formation can lead to
neurotoxicity and increased neurotransmitter
release. FK506 and CsA protect neurons
against NMDA neurotoxicity by inhibiting the
calcineurin-dependent activation of nNOS.
These drugs may also reduce the NMDA-
stimulated neurotransmitter release by the
same mechanism.
neurons from ischemic damage and b-amyloid peptide- inhibits NOS catalytic activity in cells, as would be ex-
pected from the increased phosphorylation of NOSinduced toxicity (Henrich-Noack et al., 1996; Prehn et
al., 1996; Ren and Flanders, 1996), and promotes axonal caused by FK506-mediated calcineurin inhibition. The
excitatory neurotransmitter glutamate, acting throughregeneration (Abe et al., 1996). Using the yeast two-
hybrid system, several groups identified an interaction N-methyl-D-aspartate (NMDA) receptors, activates nNOS,
resulting in increased cGMP production secondary tobetween FKBP12 and the type I TGFb receptor (Wang et
al., 1994; Okadome et al., 1996). This interaction involves nitric oxide (NO) activation of guanylyl cyclase (Snyder,
1992). While glutamate in low levels acts as a neuro-the leucine±proline 193±194 dipeptide of the type I TGFb
receptor (Charng et al., 1996), analogous to the inter- transmitter, high concentrations of glutamate released
in vascular stroke cause neurotoxicity by stimulation ofactions observed between FKBP12 and the calcium
channels described above. Evidence demonstrating the NMDA receptors (Choi, 1988). The involvement of NO in
glutamate-mediated excitotoxicity is based on findingsphysiologic significance of this interaction has been
conflicting. While some investigators observed no sig- that NOS inhibitors and nNOS gene knockout substan-
tially reduce neural damage in NMDA-treated culturesnificant contribution toTGFb signaling by FKBP12 (Charng
et al., 1996; Okadome et al., 1996), others have demon- and following vascular stroke (Yun et al., 1996). These
findings suggest that FK506, by inhibiting calcineurin,strated that disruption of the association betweenFKBP12
and type I TGFb receptor leads to enhanced signaling decreases NO formation (Figure 5). FK506 does diminish
the elevated cGMP levels following NMDA treatment ofthrough the receptor (Wang et al., 1996; Chen et al.,
cortical cultures, and low nanomolar concentrations of1997). In mice with targeted deletion of the gene for
FK506 or CsA block NMDA neurotoxicity in cortical cul-FKBP12, TGFb signaling appears normal (Shou et al.,
tures (Dawson et al., 1993).1998). However, all parameters of TGFb signaling were
Based on these findings, Sharkey and Butcher (1994)not evaluated, and mechanisms compensating for the
demonstrated that FK506 administration diminishes neu-loss of FKBP12 may have arisen during embryonic de-
ral tissue damage following middle cerebral artery oc-velopment.
clusion in rats. The observation that these effects areThe yeast two-hybrid system has also been employed
blocked by rapamycin suggests a role for calcineurinto identify another protein that binds FKBP12, desig-
inhibition in neuroprotection. Consistent with this hy-nated FKBP-associated protein-48 (FAP-48) (Chambraud
pothesis, antistroke effects have also been reportedet al., 1996). FAP-48 associates with FKBP59, as well
with CsA (Coimbra et al., 1997, Soc. Neurosci., ab-as FKBP12, but the physiologic significance of these
stract). Recently, Butcher et al. (1997) observed thatassociations is unclear.
while the administration of either FK506 or CsA can
Immunophilin Ligands Prevent Neurotoxicity reduce ischemic brain damage in rats, these drugs can-
not protect animals against quinolinate-induced excito-and Vascular Stroke Damage
The notion that immunophilins play a role in neuro- toxicity (Butcher et al., 1997). This suggests that the
in vivo neuroprotective effects of immunophilin ligandstoxicity came from initial studies of calcineurin sub-
strates. Treating brain homogenates with FK506 resulted may involve mechanisms distinct from NMDA-mediated
signaling pathways.in increased phosphorylation levels of numerous pro-
teins, one of which was neuronal nitric oxide synthase The neuroprotective actions of immunophilin ligands
extend to other forms of neurotoxicity. CsA and FK506(nNOS) (Dawson et al., 1993). nNOS can be phosphory-
lated by several kinases, including PKC, resulting in inhi- derivatives provide pronounced protection against neu-
rotoxicity elicited by the b-amyloid peptide (Pasinettibition of catalytic activity (Bredt et al., 1992). FK506
Review
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Figure 6. Regulation of Neurotransmitter Re-
lease by Dynamin I and Immunophilin Ligands
Cellular depolarization opens voltage-gated
calcium channels and increases intracellular
calcium concentration. Intracellular calcium
activates both PKC and calcineurin, which
exert opposing effects on the phosphoryla-
tion state of the GTPase dynamin I. Phos-
phorylation of dynamin I by PKC increases
its GTPase activity, leading to increased neu-
rotransmitter release secondary to an in-
creased rate of vesicle recycling. Inhibition of
calcineurin by either Cyp±CsA or FKBP12±
FK506 complex leads to enhanced phos-
phorylation of dynamin I and a subsequent
increase in depolarization-evoked neurotrans-
mitter release.
and Aisen, 1997, Soc. Neurosci., abstract) and serum activity (Robinson et al., 1993). Dynamin I is also a cal-
deprivation of cortical cultures (Hugon et al., 1997, Soc. cineurin substrate (Liu et al., 1994); accordingly,CsA and
Neurosci., abstract). FK520 treatment enhance dynamin I phosphorylation
The ability of immunophilin ligands to block neurotox- (Figure 6).
icity in numerous models of important neurological dis- Thus, immunophilins and their ligands probably regu-
eases may have clinical relevance. Drugs such as FK506 late neurotransmitter release by modulating calcineurin
penetrate the blood±brain barrier reasonably well and activity. Whether transmitter release is increased or de-
are already commercially marketed, so therapeutic eval- creased in a given circumstance depends on the relative
uation may be relatively straightforward. prominence of individual calcineurin substrates such as
nNOS or dynamin I. Modulation by immunophilins of
calcineurin activity in vivo may be determined by endog-Immunophilins Regulate Neurotransmitter Release
enous ligands of the immunophilins such as the IP3 andInhibition of NOS activity by immunophilin ligands may
ryanodine receptors. Other endogenous proteins thatalso account for influences on neurotransmitter release.
directly regulate calcineurin activity, such as cain andLow nanomolar concentrations of FK506 reduce gluta-
AKAP-79, may also be involved in the modulation ofmate release from NMDA-stimulated striatal synapto-
somes and also diminish acetylcholine and dopamine neurotransmitter release.
release from PC12 cells following differentiation elicited
by nerve growth factor (NGF) (Steiner et al., 1996). A
Immunophilins Mediate Nerve Regenerationconcentration of FK506 as low as 0.1 nM is effective in
Early work examining immunophilins in the nervous sys-PC12 cells. Inhibitors of NOS also block neurotransmit-
tem provided several clues to a link between neuronalter release (Hirsch et al., 1993). Since inhibition of cal-
regeneration and immunophilins. The relatively high ex-cineurin leads to decreased NOS activity secondary to
pression levels of FKBP12 in peripheral nerves and itsenhanced phosphorylation, inhibition of neurotransmit-
presence in the growth cones of developing neuronster release observed in the aforementioned experimen-
suggested a potential role in nerve growth. Additionally,tal systems in the presence of FK506 and CsA likely
lesions of the sciatic or facial nerve markedly augmentresults from reduced NO formation (Figure 5).
mRNA levels for FKBP12 in the facial and lumbar nuclei,In contrast, in synaptosomes depolarized by the po-
respectively (Lyons et al., 1995).tassium channel blocker 4-aminopyridine, treatment
In PC12 cells, FK506 substantially enhances neuritewith CsA or FK520, an analog of FK506 that also inhibits
outgrowth, with half-maximal effects occurring at aboutcalcineurin, augments the release of glutamate (Nichols
0.1 nM (Lyons et al., 1994). Rapamycin is neurotrophicet al., 1994). In this system, the stimulation of neuro-
for PC12 cellswith similar potency (Steiner et al., 1997a).transmitter release in the presence of immunophilin li-
FK506 stimulates PC12 cells' neurite outgrowth only ingands parallels increased phosphorylation of a promi-
the presence of NGF and enhances the neurotrophicnent synaptic protein, dynamin I. Dynamin I is a GTPase
potency of NGF about 10-fold (Lyons et al., 1994). Inwhose activity regulates the rate of synaptic vesicle re-
sensory ganglia, FK506 enhances neurite outgrowth incycling, and hence the rate of neurotransmitter release
the absence of exogenous NGF, perhaps because(De Camilli and Takei, 1996; Urrutia et al., 1997). Phos-
phorylation of dynamin I by PKC activates its GTPase Schwann cells in the ganglia synthesize the necessary
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Figure 7. Neurotrophic Actions of Immuno-
philin Ligands
Picomolar concentrations of the immunophi-
lin ligand GPI-1046 promote neurite out-
growth in chicken sensory ganglia.
small amounts of neurotrophic molecules. Concentra- and related compounds more suitable candidates for
treating neurological diseases.tions of FK506 in the picomolar range produce detect-
able stimulation in rat (Lyons et al., 1994) and chick The neurotrophic effects of the immunophilin ligands
are demonstrable in models of neurologic disability indorsal root ganglia (Steiner et al., 1997a).
Initial efforts to explain the neurotrophic effects fo- intact animals. FK506 stimulates regrowth of damaged
sciatic nerves and functional recovery (Gold et al., 1994,cused on calcineurin substrates, especially GAP-43.
GAP-43 (growth associated protein of 43 kDa) is se- 1995; Steiner et al., 1997a). Nonimmunosuppressive de-
rivatives are also effective. Thus, GPI-1046 (Steiner etlectively localized to developing or regenerating neu-
rons (Basi et al., 1987). Phosphorylation of GAP-43 is al., 1997b), V-10,367 (Gold et al., 1997), and L-685,818
(Steiner et al., 1997a), a nonimmunosuppressive FK506associated with enhanced function, and GAP-43 is a
calcineurin substrate whose phosphorylated levels are derivative, augment regrowth of damaged sciatic nerves.
GPI-1046 also stimulates regrowth of damaged neuronsincreased by FK506 treatment (Steiner et al., 1992).
Moreover, following facial nerve crush, both GAP-43 in the brain. Following lesion of serotonin neurons with
P-chloroamphetamine, animals receiving GPI-1046 dis-and FKBP12 mRNA levels in the facial nucleus increase
dramatically with similar time courses (Lyons et al., play double the density of serotonin-positive neuronal
fibers in the cerebral cortex, compared with untreated1995).
Strong evidence that calcineurin inhibition does not animals (Steiner et al., 1997b). GPI-1046 similarly stimu-
lates the regrowth of cholinergic neurons in the brainmediate neurotrophic effects comes from studies with
close structural derivatives of FK506, CsA, and rapa- following fimbria±fornix lesions (Guo et al., 1997, Soc.
Neurosci., abstract).mycin that bind with high affinity to the immunophilins.
However, complexes of these derivatives with the immu- The most extensive central nervous system studies
have been conducted with dopaminergic neurons. Le-nophilins fail to bind or inhibit calcineurin and are not
immunosuppressive (Steiner et al., 1997a). These non- sions with 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine
(MPTP) or 6-hydroxydopamine (6-OHDA) elicit massiveimmunosuppressive derivatives are neurotrophic for
PC12 cells and sensory ganglia with potencies and max- destruction of nigral dopaminergic neurons (Gerlach et
al., 1991). These are the same neurons that degenerateimal effects similar to their immunosuppressive analogs.
Using principles of rational drug design, novel com- in patients with Parkinson's disease, making MPTP and
6-OHDA treatment experimental paradigms for the studypounds that can bind FKBP12, but not calcineurin, have
been synthesized. One such compound, 3-(3-pyridyl)- of this disorder. Treatment with GPI-1046 before, during,
or after the MPTP lesions substantially restores the dam-1-propyl (2S) -1-(3,3-dimethyl-1,2 -dioxopentyl)-2-pyr-
rolidinedinecarboxylate (GPI-1046) (Figure 1), inhibits aged dopamine neurons, as demonstrated by increased
striatal tyrosine hydroxylase staining and reversal ofFKBP12 rotamase activity with a Ki of 7.5 nM and fails
to inhibit T cell proliferation at concentrations up to haloperidol-induced catalepsy and akinesia (Steiner et
al., 1997b; Steiner et al., 1997, Soc. Neurosci., abstract).10 mM (Steiner et al., 1997b). GPI-1046 elicits neurite
outgrowth in chick sensory ganglia at 1 pM concentra- In rats lesioned with unilateral intranigral 6-OHDA ad-
ministration, GPI-1046 elicits both morphological andtion with 50% maximal effect at 58 pM (Figure 7). Similar
findings have been observed with other nonimmu- functional recovery, with increased striatal catechola-
mine levels and a reduction in amphetamine-inducednosuppressive FK506 analogs such as V-10,367 (Gold et
al., 1997). The increased potency and reduced immune rotations (Ross et al., 1997, Soc. Neurosci., abstract;
Steiner et al., 1997b).suppression relative to FK506 make GPI-1046, V-10,367,
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